Of all patients, 59% were male and 41% female, 55% presented with macroscopic hematuria compared to 45% with microscopic hematuria. A total of 115 patients was diagnosed with urothelial cancer. The assay resulted in an AUC of 0.95 and a sensitivity of 93%, a specificity of 81% and a NPV of 99%. All 4 upper tract tumors were identified.
In summary, patients referred for hematuria the urine assay was able to predict the absence of bladder cancer, especially in the microhematuria patient population, with very high accuracy. This assay may be implemented clinically to select patients for diagnostic cystoscopy.
Presented by: Kim E.M. van Kessel, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam
Written by: Stephen B. Williams, M.D., Associate Professor, Division of Urology, The University of Texas Medical Branch, Galveston, TX. and Ashish M. Kamat, M.D. Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX at the 16th Annual Meeting of the International Bladder Cancer Network (IBCN) October 11-13, 2018 - the Inntel Hotels Rotterdam Centre, Rotterdam, The Netherlands